« | Home | »

FDA approves Striverdi Respimat for COPD

By jeremyc | August 1, 2014

A new chronic obstructive pulmonary disease (COPD) treatment medication has been approved by the US Food and Drug Administration (FDA). The medication in question is chronic obstructive pulmonary disease (COPD), and it has been approved to treat Boehringer Ingelheim’s COPD.

The medication is part of a group of drugs called long-acting beta-adrenergic agonists (LABAs) that relaxes the muscles around the lung airways and thus reducing COPD symptoms. The approval was given after the medication’s efficacy and safety was tested by researchers on over 3,000 people. The FDA noted that patients who tool this medication had better lung function than the placebo control group.

Curtis Rosebraugh, MD, MPH, director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation, said, “The availability of this new long-term maintenance medication provides an additional treatment option for the millions of Americans who suffer with COPD.”

The new medication has also been ordered by the FDA to keep a boxed warning that LABAs increase asthma-related death risk. Striverdi Respimat itself has not been approved for asthma treatment and is effectiveness and safety in treating the condition has not yet been tested or verified.

Topics: | COPD | No Comments »

Comments are closed.